• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寻找适用于铅/铋体内发生器的配体。

Search of ligands suitable for Pb/Bi in vivo generators.

作者信息

Bartoś Barbara, Lyczko Krzysztof, Kasperek Agata, Krajewski Seweryn, Bilewicz Aleksander

机构信息

Centre for Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 03-195, Warszawa, Poland.

出版信息

J Radioanal Nucl Chem. 2013;295(1):205-209. doi: 10.1007/s10967-012-2238-4. Epub 2012 Sep 19.

DOI:10.1007/s10967-012-2238-4
PMID:26224928
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4513904/
Abstract

The short half-life of Bi and Bi limits the application of these radionuclides in α radionuclide therapy. The labeling of biomolecules with Pb (mother nuclide of Bi) instead of Bi or Bi has the advantage of obtaining a conjugate with a half-life of 10.6 h, compared with of 60 min for Bi or 46 min for Bi. Previous attempts to prepare a potential in vivo generator with Pb complexed by the DOTA chelator failed, because about 36 % of Bi was reported to escape as a result of the radioactive decay [Formula: see text]. Herein, we report studies on the stability of the Pb complexes with eight selected polydentate ligands, which demonstrate high affinity for 3+ metal cations. From the ligand studied DOTP and BAPTA show a sufficient Pb labeling yields but only Pb-DOTP complex is stable in isotonic solution of sodium chloride making this way radioactivity level of released Bi is below the limit of detection. It should be emphasized that the DOTP complex is stable only in the case when the concentration of free DOTP exceeds 10 M.

摘要

铋-212和铋-213的短半衰期限制了这些放射性核素在α放射性核素治疗中的应用。用铅(铋-212的母核素)而非铋-212或铋-213标记生物分子的优势在于可获得半衰期为10.6小时的缀合物,相比之下,铋-212的半衰期为60分钟,铋-213的半衰期为46分钟。此前尝试制备由DOTA螯合剂络合铅的潜在体内发生器的努力失败了,因为据报道约36%的铋-212会因放射性衰变而逸出[公式:见原文]。在此,我们报告了对铅与八种选定多齿配体形成的络合物稳定性的研究,这些配体对3 +金属阳离子显示出高亲和力。在所研究的配体中,二乙基三胺五乙酸(DOTP)和1,2 -双(2 -氨基苯氧基)乙烷 - N,N,N',N'-四乙酸(BAPTA)显示出足够的铅标记产率,但只有铅 - DOTP络合物在氯化钠等渗溶液中稳定,使得释放的铋-212的放射性水平低于检测限。应当强调的是,只有当游离DOTP的浓度超过10 M时,DOTP络合物才稳定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce7/4513904/5f96c3e030ce/10967_2012_2238_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce7/4513904/5f96c3e030ce/10967_2012_2238_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce7/4513904/5f96c3e030ce/10967_2012_2238_Fig1_HTML.jpg

相似文献

1
Search of ligands suitable for Pb/Bi in vivo generators.寻找适用于铅/铋体内发生器的配体。
J Radioanal Nucl Chem. 2013;295(1):205-209. doi: 10.1007/s10967-012-2238-4. Epub 2012 Sep 19.
2
Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics.通过DOTA的四磷酸类似物高效形成惰性Bi-213螯合物:迈向改进的α疗法。
EJNMMI Res. 2018 Aug 8;8(1):78. doi: 10.1186/s13550-018-0431-3.
3
Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.使用体内212Pb/212Bi发生器对荷瘤小鼠进行预靶向放射免疫治疗。
Nucl Med Biol. 2005 Oct;32(7):741-7. doi: 10.1016/j.nucmedbio.2005.06.009.
4
Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with (44m/44)Sc and experimental evidence of the feasibility of an in vivo PET generator.用(44m/44)Sc对DOTA和DOTA肽进行放射性标记的反应条件优化及体内PET发生器可行性的实验证据
Nucl Med Biol. 2014 May;41 Suppl:e36-43. doi: 10.1016/j.nucmedbio.2013.11.004. Epub 2013 Nov 16.
5
Mathematical Modeling of Alpha Particle Generators and Chelator Stability.阿尔法粒子发生器和螯合剂稳定性的数学建模。
Cancer Biother Radiopharm. 2023 Oct;38(8):528-535. doi: 10.1089/cbr.2020.4112. Epub 2021 Jan 21.
6
Hampa─Versatile Chelator for [Pb]Pb, [Bi]Bi, and [Ac]Ac.Hampa─一种用于 [Pb]Pb、[Bi]Bi 和 [Ac]Ac 的多功能螯合剂。
Inorg Chem. 2022 Jun 20;61(24):9119-9137. doi: 10.1021/acs.inorgchem.2c00636. Epub 2022 Jun 9.
7
DTPA complexation of bismuth in human blood serum.人血清中双硫腙与铋的络合作用。
Dalton Trans. 2012 Jul 28;41(28):8615-23. doi: 10.1039/c2dt30230f. Epub 2012 Jun 7.
8
Coupling a gamma-ray detector with asymmetrical flow field flow fractionation (AF4): Application to a drug-delivery system for alpha-therapy.将伽马射线探测器与非对称流场流分离(AF4)相耦合:在用于放射治疗的药物输送系统中的应用。
J Chromatogr A. 2018 Oct 26;1573:107-114. doi: 10.1016/j.chroma.2018.08.065. Epub 2018 Sep 1.
9
Biodistribution study of Pb progeny released from intravenously applied Ra labelled TiO nanoparticles in a mouse model.静脉注射放射性标记 TiO2 纳米颗粒后体内 Pb 产物的生物分布研究。
Nucl Med Biol. 2024 Mar-Apr;130-131:108890. doi: 10.1016/j.nucmedbio.2024.108890. Epub 2024 Feb 19.
10
Preparation of Pb-labeled monoclonal antibody using a novel Ra-based generator solution.使用新型基于镭的发生器溶液制备铅标记单克隆抗体。
Nucl Med Biol. 2017 Aug;51:1-9. doi: 10.1016/j.nucmedbio.2017.04.005. Epub 2017 Apr 26.

引用本文的文献

1
Pb in targeted radionuclide therapy: a review.靶向放射性核素治疗中的铅:综述
EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):34. doi: 10.1186/s41181-025-00362-7.
2
Scalability study on [La]LaCl production with a focus on potential clinical applications.关于[镧]氯化镧生产的可扩展性研究,重点关注潜在的临床应用。
EJNMMI Radiopharm Chem. 2024 Aug 15;9(1):60. doi: 10.1186/s41181-024-00292-w.
3
Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for Pb and Pb-Based Theranostics.一种与放射性肽偶联用于铅及基于铅的诊疗的铅特异性螯合剂(PSC)的临床前评估。

本文引用的文献

1
Towards translation of 212Pb as a clinical therapeutic; getting the lead in!迈向 212Pb 作为临床治疗剂的转化;引领潮流!
Dalton Trans. 2011 Jun 21;40(23):6068-76. doi: 10.1039/c0dt01387k. Epub 2011 Mar 4.
2
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.用 213Bi-DOTA-[Thi8,Met(O2)11]-substance P 对功能上重要部位的胶质瘤进行靶向α-放射性核素治疗:一项初步试验。
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44. doi: 10.1007/s00259-010-1385-5. Epub 2010 Feb 16.
3
Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.
Pharmaceutics. 2023 Jan 26;15(2):414. doi: 10.3390/pharmaceutics15020414.
4
Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.通过双重靶向 PSMA 和白蛋白来调节 Actinium-225 标记的大环衍生放射性缀合物的药代动力学特征。
Theranostics. 2022 Oct 17;12(17):7203-7215. doi: 10.7150/thno.78043. eCollection 2022.
5
Efficient Production of the PET Radionuclide La for Theranostic Purposes in Targeted Alpha Therapy Using the Ba(p,2n)La Reaction.利用Ba(p,2n)La反应在靶向α治疗中高效生产用于诊疗目的的PET放射性核素镧。
Pharmaceuticals (Basel). 2022 Sep 21;15(10):1167. doi: 10.3390/ph15101167.
6
Dosimetry in Radiopharmaceutical Therapy.放射性药物治疗中的剂量学。
J Nucl Med. 2022 Oct;63(10):1467-1474. doi: 10.2967/jnumed.121.262305.
7
Pb: Production Approaches and Targeted Therapy Applications.铅:生产方法与靶向治疗应用。 (注:原文中Pb常见化学元素“铅”,这里按字面翻译为“铅”,感觉不太符合语境,但根据要求未做其他处理,如果有上下文或许能更准确翻译,比如Production Approaches and Targeted Therapy Applications是某个研究中关于铅的特定内容,可能是“铅基:生产方法与靶向治疗应用” )
Pharmaceutics. 2022 Jan 13;14(1):189. doi: 10.3390/pharmaceutics14010189.
8
Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications.基于α发射体的纳米放射性药物:医学应用的最新进展
Pharmaceutics. 2021 Jul 23;13(8):1123. doi: 10.3390/pharmaceutics13081123.
9
Production, purification, and radiolabeling of the Pb/Pb theranostic pair.Pb/Pb诊疗组合的制备、纯化及放射性标记
EJNMMI Radiopharm Chem. 2021 Feb 1;6(1):6. doi: 10.1186/s41181-021-00121-4.
10
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.靶向α治疗:放射性核素生产、放射化学及应用的进展
Pharmaceutics. 2020 Dec 31;13(1):49. doi: 10.3390/pharmaceutics13010049.
多模态疗法:用紫杉醇增强高线性能量传递辐射治疗播散性腹膜疾病。
Clin Cancer Res. 2008 Aug 15;14(16):5108-15. doi: 10.1158/1078-0432.CCR-08-0256.
4
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.用211At标记的单克隆抗体进行靶向α粒子放射治疗。
Nucl Med Biol. 2007 Oct;34(7):779-85. doi: 10.1016/j.nucmedbio.2007.03.007. Epub 2007 May 11.
5
Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.使用靶向HER2的(212)Pb标记放射免疫偶联物对播散性腹膜疾病进行α粒子放射免疫治疗。
Cancer Biother Radiopharm. 2005 Oct;20(5):557-68. doi: 10.1089/cbr.2005.20.557.
6
Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.使用体内212Pb/212Bi发生器对荷瘤小鼠进行预靶向放射免疫治疗。
Nucl Med Biol. 2005 Oct;32(7):741-7. doi: 10.1016/j.nucmedbio.2005.06.009.
7
Melanoma therapy via peptide-targeted {alpha}-radiation.通过肽靶向α辐射治疗黑色素瘤
Clin Cancer Res. 2005 Aug 1;11(15):5616-21. doi: 10.1158/1078-0432.CCR-05-0619.
8
Radioimmunotherapy with alpha-particle emitting radionuclides.使用发射α粒子的放射性核素进行放射免疫治疗。
Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96.
9
Nonuniformity of tumor dose in radioimmunotherapy.放射免疫治疗中肿瘤剂量的不均匀性。
J Nucl Med. 1990 Jan;31(1):75-83.